Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress - The Manila Times
Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress The Manila Times
The health section covers stories about medical progress, recovery, and wellbeing. We look for genuine advances: new therapies clearing regulatory hurdles, diseases being eradicated in specific regions, communities improving public health outcomes through evidence-based programs. Celebrity wellness trends and supplement marketing do not make the cut.
We speak to Daniel who has been cured of sickle cell
Researchers found that semaglutide, the active ingredient in Ozempic and Wegovy, slowed biological aging markers in adul…
Affordable healthcare innovation will define Viksit Bharat 2047, says Dr R A Mashelkar at FICCI Legends Series Pharmabiz…
Scientists Find Intense Breathwork Can Trigger Psychedelic-Like States and Lasting Psychological Changes The Debrief